Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis

Chest

Volumn 127, Issue 6, 2005, Pages 2231-2236

  Chodosh, Sanford ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Acute bronchitis; Acute exacerbation of chronic bronchitis; Antibiotics; Disease free interval; Infection free interval

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFACLOR; CEFALEXIN; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GEMIFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; HUMAN; MEDICAL DOCUMENTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; ACUTE DISEASE; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; INCIDENCE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; RECURRENT DISEASE; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BRONCHITIS, CHRONIC; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; GRAM-NEGATIVE BACTERIA; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 21844464587     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.6.2231     Document Type: Article

References (34)

1. Halpern MT, Higashi MK, Bakst AW, et al. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J Manag Care Pharm 2003; 9:353-359
2. Sethi S. Infectious exacerbation of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999; 43(suppl A):97-105
3. Obaji A, Sethi S. Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? Drugs Aging 2001; 18:1-11
4. Saint S, Flaherty KR, Abrahamse P, et al. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther 2001; 23:499-512
5. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422
6. Chodosh S. Acute bacterial exacerbations in bronchitis and asthma. Am J Med 1987; 82(suppl 4A):154-163
7. Wilkinson TMA, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169:1298-1303
8. Gonzales R, Malone DC, Maselli JH, et al. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33:757-762
9. Gonzales R, Steiner JF, Lum A, et al. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999; 281:1512-1519
10. Chodosh S, Eichel B, Ellis C, et al. Comparison of trimethoprim- sulfamethoxazole with ampicillin in acute infectious exacerbations of chronic bronchitis: a double-blind crossover study. Rev Infect Dis 1982; 4:517-527
11. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001; 33(suppl 3):S187-S192
12. Baigelman W, Chodosh S, Pizzuto D, et al. Quantitative sputum gram stains in chronic bronchial disease. Lung 1979; 156:265-270
13. Chodosh S. Examination of sputum cells. N Engl J Med 1970; 282:854-857
14. Chodosh S. Valid information from sputum: don't throw out the baby with the bath water. Chest 1999; 116:6-8
15. Medici TC, Chodosh S. Sputum cell dynamics in bacterial exacerbations of chronic bronchial disease. Arch Intern Med 1972; 129:597-603
16. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001; 134:595-599
17. Flaherty KR, Saint S, Fendrick AM, et al. The spectrum of acute bronchitis: using baseline factors to guide empirical therapy. Postgrad Med 2001; 109:39-47
18. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134:600-620
19. Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis 1999; 28:1344-1345
20. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852
21. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58:589-593
22. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 2000; 27:730-738
23. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27:722-729
24. Chodosh S, Tuck J, Stottmeier KD, et al. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis: a double-blind crossover study. Am J Med 1989; 87(Suppl 5A):107S-112S
25. Chodosh S, Tuck J, Pizzuto D. Comparative trials of doxycycline versus amoxicillin, cephalexin and enoxacin in bacterial infections in chronic bronchitis and asthma. Scand J Infect Dis Suppl 1988; 53:22-28
26. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58:680-685
27. Murphy TF, Brauer AL, Schiffmacher AT, et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:266-272
28. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-471
29. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-295
30. Read RC, Kuss A, Berrisoul F, et al. The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis. Respir Med 1999; 93:252-261
31. Wilson R, Schentag JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002; 24:639-652
32. Grassi C, Casali L, Curti E, et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002; 14:597-608
33. Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125:953-964
34. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152:1316-1320